NCT03284853

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 436 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure

Conditions

• Open Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Netarsudil/Latanoprost 0.02%/0.005%	Topical sterile ophthalmic solution
DRUG	GANFORT®	Topical sterile ophthalmic solution

Timeline

• Start date: 2017-09-05
• Primary completion: 2020-11-06
• Completion: 2020-11-06
• First posted: 2017-09-15
• Last updated: 2022-01-31
• Results posted: 2022-01-19

Locations

68 sites across 11 countries: Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Poland, Spain, United Kingdom

Regulatory

• FDA-regulated drug study